ArticleThe American journal of tropical medicine and hygiene2015
Counterfeit drug penetration into global legitimate medicine supply chains: a global assessment.
Article in The American journal of tropical medicine and hygiene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Rapid Identification of Counterfeit Biopharmaceuticals using Portable Fourier Transform Infrared Spectroscopy.AAPS PharmSciTech · 2026Article
- Content analysis of illegal online advertisements for hypertension-related drugs and supplements in Taiwan.BMC public health · 2026Article
- Pharmabiome analyses in tandem with chemometrics can help trace the provenance of falsified medicines: A proof-of-concept study.Forensic science international. Genetics · 2026Article
- Barriers to accessing high-quality cancer medicines in Cameroon. A qualitative study of the views and practices of regulators and frontline healthcare providers.PLOS global public health · 2026Article
- Promising Practices in Capacity Development for Health Supply Chains in Resource-Constrained Countries.Global health, science and practice · 2025Review
- Redefining Counterfeit Medicines and Updating the Legal Framework to Address Falsified Medicines: A Qualitative Policy Review.Acta medica Philippina · 2025Article
- Knowledge, attitudes and practices on substandard and falsified medicines for human and animal use in Wakiso district, Uganda.Journal of pharmaceutical policy and practice · 2025Article
- Economic barriers to prevent the smuggling of health goods in Iran.BMJ global health · 2024Article
- Framework of Guidelines for Management of CKD in Asia.Kidney international reports · 2024Article
- Investigating the Presence of Falsified and Poor-Quality Fixed-Dose Combination Artemether-Lumefantrine Pharmaceutical Dosage Forms in Kumasi, Ghana.Advances in pharmacological and pharmaceutical sciences · 2024Article
- Tackling Counterfeit Drugs: The Challenges and Possibilities.Pharmaceutical medicine · 2023Review
- Assessment of quality of essential medicines in public health care facilities of Nepal: Findings of nationwide study.PLOS global public health · 2023Article
- Multifactor Quality and Safety Analysis of Antimicrobial Drugs Sold by Online Pharmacies That Do Not Require a Prescription: Multiphase Observational, Content Analysis, and Product Evaluation Study.JMIR public health and surveillance · 2022Article
- Article
- The quality of veterinary medicines and their implications for One Health.BMJ global health · 2022Article
- Article
- The adulterated XANAX pill: a fatal intoxication with etizolam and caffeine.International journal of legal medicine · 2020Article
- Country Income Is Only One of the Tiles: The Global Journey of Antimicrobial Resistance among Humans, Animals, and Environment.Antibiotics (Basel, Switzerland) · 2020Review
- The ghost in the data: Evidence gaps and the problem of fake drugs in global health research.Global public health · 2020Review
- Counterfeit Rabies Vaccines: The Philippine Experience.Open forum infectious diseases · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Counterfeit medicines are a global public health risk. We assess counterfeit reports involving the legitimate supply chain using 2009-2011 data from the Pharmaceutical Security Institute Counterfeit Incident System (PSI CIS) database that uses both open and nonpublic data sources. Of the 1,510 identified CIS reports involving counterfeits, 27.6% reported China as the source country of the incident/detection. Further, 51.3% were reported as counterfeit but the specific counterfeit subcategory was not known or verifiable. The most prevalent therapeutic category was anti-infectives (21.1%) with most reports originating from health-related government agencies. Geographically, Asian and Latin American regions and, economically, middle-income markets were most represented. A total of 127 (64.8%) of a total of 196 countries had no legitimate supply chain CIS counterfeit reports. Improvements in surveillance, including detection of security breaches, data collection, analysis, and dissemination are urgently needed to address public health needs to combat the global counterfeit medicines trade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.